Table 1.
Maternal and reproductive parameters at the time of cesarean section in the HFD-dNONcNZO mice and those receiving tacrolimus or metformin
| Maternal BWt (g) | Mean BG (mmol/L) | No. of litters | Litters with viable fetuses | No. total implants | No. total fetuses | Total viable fetuses | % viable fetuses | Implantation sites/litter (mean ± SD) | No. resorption/litter (mean ± SD) % (mean ± SD) | No. fetuses/litter (mean ± SD) | Viable fetuses/litter at necropsy (mean ± SD) (%) (mean ± SD) | Fetal viability 1 h post necropsy (%) viable at parturition | Male:female ratio | Fetal wt. (m) | Placental wt. (g) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HFD-dNONCNZO | 57.5 ± 8.1 | 14.67 ± 1.96 | 4 | 3 | 21 | 10 | 3 | 30 | 5.25 ± 1.17 | 2.75 ± 0.50 (55 ± 10.6) | 2.5 ± 1.29 | 0.75 ± 0.50 (33.0 ± 19.1) | 0 | 50:50 | 1.30 ± 0.57 | 0.213 ± 0.14 |
| TACRO (0.05 mg/kg) | 38.7 ± 0.81a | 7.60 ± 0.71a | 3 | 3 | 26 | 23 | 22 | 96 | 8.67 ± 0.58a | 1.0 ± 1.73 (16.5 ± 19.1) | 7.67 ± 1.53a | 7.33 ± 1.15 (96.3 ± 7.78) | 91.0 ± 10.1b | 40:60 | 1.01 ± 0.325 | 0.181 ± 0.050a |
| TACRO (0.1 mg/kg) | 45.07 ± 3.72 | 7.13 ± 1.59a | 3 | 3 | 23 | 19 | 18 | 95 | 7.13 ± 1.53 | 1.33 ± 0.71 (16.7 ± 6.5) | 6.33 ± 1.53a | 6.0 ± 2.0 (93.3 ± 11.5)b | 89.0 ± 19.1b | 62:38 | 1.37 ± 0.209 | 0.204 ± 0.024 |
| Metformin (200 mg/dL) | 54.22 ± 1.63a | 9.62 ± 2.63a | 3 | 3 | 27 | 21 | 17 | 81 | 9.0 ± 2.05a | 2.0 ± 2.65 (18.7 ± 23.5) | 7.00 ± 1.00a | 5.67 ± 1.15 (82.0 ± 40.1) | 80.0 ± 41.5b | 52:48 | 0.847 ± 0.33b | 0.1684 ± 0.029b |
HFD-dNONcNZO data are presented as mean ± SD
TACRO tacrolimus, BG blood glucose
aSignificantly different from HFD-dNONcNZO, p < 0.05 Kruskal–Wallis
bSignificantly different from HFD-dNONcNZO, p < 0.01 Kruskal–Wallis